



Fax completed form to: (855) 840-1678
 If this is an URGENT request, please call (800) 882-4462
 (800.88.CIGNA)

Nulibry (fosdenopterin)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication Requested: <input type="checkbox"/> Nulibry 9.5mg powder for injection					
ICD10:		Dose and Quantity:		Duration of therapy:	
Frequency of therapy:					
What is your patient's current weight? _____ lb/kg Is this a new start or continuation of therapy? If your patient has already begun treatment with drug samples, please choose "new start of therapy." <div style="text-align: right;">New Start <input type="checkbox"/> Continuation of Therapy <input type="checkbox"/></div> <div style="text-align: right;">Start date: _____</div>					
(if continued therapy) Is your patient having a beneficial clinical response to therapy with this drug? Yes <input type="checkbox"/> No <input type="checkbox"/>					
(if continued therapy) Was the patient previously started on this medication while genetic testing results were still pending? <div style="text-align: right;">Yes <input type="checkbox"/> No <input type="checkbox"/></div>					
(if yes) Has genetic testing NOW confirmed a mutation resulting in MoCD (for example, in the MOCS1 gene)? Yes <input type="checkbox"/> No <input type="checkbox"/>					
(if no) Please explain continued use. _____					
Where will this medication be obtained? <input type="checkbox"/> Accredo Specialty Pharmacy** <input type="checkbox"/> Prescriber's office stock (billing on a medical claim form) <input type="checkbox"/> Home Health / Home Infusion vendor**Cigna's nationally preferred specialty pharmacy <input type="checkbox"/> Other (please specify): _____					
<i>**Medication orders can be placed with Accredo via E-prescribe - Accredo (1640 Century Center Pkwy, Memphis, TN 38134-8822 NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557</i>					
Facility and/or doctor dispensing and administering medication: Facility Name: _____ State: _____ Tax ID#: _____ Address (City, State, Zip Code): _____					
Is this infusion occurring in a facility affiliated with hospital outpatient setting? Yes <input type="checkbox"/> No <input type="checkbox"/>					
If yes- Is this patient a candidate for re-direction to an alternate setting after 1-2 infusions (such as AIS, MDO, home) with assistance of a Specialty Care Option Case Manager? Yes <input type="checkbox"/> No <input type="checkbox"/>					
NOTE: Per some Cigna plans, infusion of medication MUST occur in the lowest cost, medically appropriate setting.					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? Yes <input type="checkbox"/> No <input type="checkbox"/>					

Clinical Information

****This drug requires supportive documentation (genetic test results, chart notes, lab/test results, etc) be attached with this request****

- Is this medication being used to treat Molybdenum cofactor deficiency (MoCD) Type A? Yes No
(if no) What is the diagnosis related? _____
(if MoCD) Has the patient underwent genetic testing that confirmed a mutation in the MOCS1 gene? Yes No
(if no) Does your patient have a suspected Molybdenum cofactor deficiency (MoCD) Type A based on clinical presentation (for example, intractable seizures, failure to thrive) and treatment is being initiated while genetic testing is pending? Yes No
(if MoCD) Is there documentation, based on the patient's current condition, that the individual is expected to derive benefit with Nulibry and the disease state is NOT considered to be too advanced? Yes No
(if MoCD) Is this medication prescribed by, or in consultation with, a pediatrician, geneticist, or a physician who specializes in molybdenum cofactor deficiency (MoCD) Type A? Yes No

Additional pertinent information (please include disease stage, prior therapy, performance status, and names/doses/admin schedule of any agents to be used concurrently):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v052521

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005